Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BTV4
UPID:
TMM43_HUMAN
Alternative names:
Protein LUMA
Alternative UPACC:
Q9BTV4; Q7L4N5; Q8NC30; Q96A63; Q96F19; Q96JX0; Q9H076
Background:
Transmembrane protein 43, also known as Protein LUMA, plays a pivotal role in maintaining nuclear envelope structure and organizing protein complexes at the inner nuclear membrane. It is essential for retaining emerin at the inner nuclear membrane and modulates innate immune signaling through the cGAS-STING pathway. Additionally, it acts as a critical signaling component in NF-kappa-B activation, positioned downstream of EGFR and upstream of CARD10. It also contributes to passive conductance current in cochlear glia-like supporting cells, necessary for hearing and speech discrimination.
Therapeutic significance:
Transmembrane protein 43 is implicated in several diseases, including Arrhythmogenic right ventricular dysplasia, familial, 5, Emery-Dreifuss muscular dystrophy 7, autosomal dominant, and Auditory neuropathy, autosomal dominant 3. These associations highlight its potential as a target for therapeutic strategies aimed at treating congenital heart disease, degenerative myopathies, and sensorineural hearing loss.